Global prevalence of SARS-CoV-2 3CL protease mutations associated with nirmatrelvir or ensitrelvir resistance.

ABSTRACT:

Background

Nirmatrelvir-ritonavir (Paxlovid) and ensitrelvir are 3-chymotrypsin-like cysteine protease (3CL^pro) inhibitors which have been approved for the treatment of COVID-19 in 2021 and 2022, respectively. Previous studies have identified 3CL^pro mutations that are associated with reduced susceptibility to these antivirals. The aim of the current study was to estimate the global prevalence of 3CL^pro inhibitor-resistant SARS-CoV-2 strains.

Methods

We compiled a list of 3CL^pro mutations which have been associated with nirmatrelvir or ensitrelvir resistance based on either viral replication or 3CL^pro activity assays, and determined their prevalence among 13.4 million sequences deposited in GISAID as of December 14, 2022,

SUBMITTER: Ip JD 

PROVIDER: S-EPMC10101811 | biostudies-literature | 2023 May

REPOSITORIES: biostudies-literature